Expertise in
14
conditions

Dr. Elisabeth Heath

Oncology
Karmanos Cancer Center
4100 John R St, 
Detroit, MI 
Clinical Trials:Currently Recruiting for 3 Trials
Expertise in
14
conditions
Karmanos Cancer Center
4100 John R St, 
Detroit, MI 

Overview

Elisabeth Heath is an Oncologist in Detroit, Michigan. Dr. Heath is highly rated in 14 conditions, according to our data. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Her clinical research consists of co-authoring 211 peer reviewed articles and participating in 30 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MI

Hospital Affiliations

Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Karmanos Cancer Center
4100 John R St, Detroit, MI 48201
Other Locations
Mayo Clinic-Rochester
5716 Cleveland St Ste 200, Virginia Beach, VA 23462

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

30 Clinical Trials

A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Avelumab, Peposertib, Radium-223
Study Phase: Phase 1/Phase 2
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: August 11, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2025
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Olaparib, Radium-223
Study Phase: Phase 1/Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib or Liver Metastases Who Have Received Prior Anti-Androgen Therapy
Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib or Liver Metastases Who Have Received Prior Anti-Androgen Therapy
Enrollment Status: Completed
Publish Date: December 18, 2025
Intervention Type: Drug
Study Drug: Cabozantinib
Study Phase: Phase 2
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Enrollment Status: Completed
Publish Date: October 28, 2025
Intervention Type: Drug, Radiation
Study Drug: Enzalutamide
Study Phase: Phase 2
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2025
Intervention Type: Drug
Study Drug: IMMU-132
Study Phase: Phase 2
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Using Music As a Tool for Distress Reduction During Cancer Treatment
Using Music As a Tool for Distress Reduction During Cancer Treatment
Enrollment Status: Completed
Publish Date: January 08, 2025
Intervention Type: Behavioral
Study Phase: Not Applicable
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
Phase II Multi-Center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Castrate Resistant Prostate Cancer
Phase II Multi-Center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: July 16, 2024
Intervention Type: Drug, Biological
Study Drugs: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981, Nivolumab
Study Phase: Phase 2
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: June 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: February 01, 2024
Intervention Type: Drug
Study Drug: FOR46 Anti-CD46 Antibody Drug Conjugate
Study Phase: Phase 1
Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)
Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Other
Study Phase: Not Applicable
Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]
Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]
Enrollment Status: Completed
Publish Date: August 04, 2023
Intervention Type: Drug, Radiation
Study Drug: Nivolumab
Study Phase: Phase 2
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)
Enrollment Status: Completed
Publish Date: July 14, 2023
Intervention Type: Drug
Study Drug: ESK981
Study Phase: Phase 2
A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer
A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drug: Muscadine Plus
Study Phase: Phase 3
A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma
A Phase 1, Open-label Study in Two Parts, Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of CCW702 in Patients With Metastatic, Castration Resistant Prostate Adenocarcinoma
Enrollment Status: Terminated
Publish Date: May 12, 2023
Intervention Type: Drug
Study Drug: CCW702 Immunotherapy
Study Phase: Phase 1
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: May 10, 2023
Intervention Type: Drug, Procedure, Other
Study Drugs: Enzalutamide, Bicalutamide, Leuprolide acetate, Goserelin acetate
Study Phase: Phase 2
Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer
Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Biological, Other
Study Drugs: HER2Bi-Armed Activated T Cells, Pembrolizumab
Study Phase: Phase 2
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
PACCT: Partnering Around Cancer Clinical Trials
PACCT: Partnering Around Cancer Clinical Trials
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers
Enrollment Status: Completed
Publish Date: August 30, 2021
Intervention Type: Drug
Study Drugs: Ciforadenant, Ciforadenant+Atezolizumab
Study Phase: Phase 1
MyPatientPal: An App to Help Patients Manage Their Cancer Care
MyPatientPal: An App to Help Patients Manage Their Cancer Care
Enrollment Status: Completed
Publish Date: March 02, 2021
Intervention Type: Other
Study Phase: Not Applicable
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Enrollment Status: Completed
Publish Date: October 06, 2020
Intervention Type: Drug, Other, Radiation
Study Phase: Phase 1
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Enrollment Status: Terminated
Publish Date: July 26, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 27 Less Clinical Trials

211 Total Publications

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP).
Journal: JCO precision oncology
Published: September 16, 2025
Similar Doctors
Shirish Gadgeel
Expertise in
15
conditions
Dr. Shirish Gadgeel
Oncology
Expertise in
15
conditions
Dr. Shirish Gadgeel
Oncology

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (486.0 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances

Shirish Gadgeel is an Oncologist in Detroit, Michigan. Dr. Gadgeel is highly rated in 15 conditions, according to our data. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy.

Expertise in
31
conditions
Dr. Philip Philip
Oncology
Expertise in
31
conditions
Dr. Philip Philip
Oncology

Henry Ford Cancer-Detroit

2800 W Grand Blvd, 
Detroit, MI 
 (486.0 miles away)
888-777-4167
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philip Philip is an Oncologist in Detroit, Michigan. Dr. Philip is highly rated in 31 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Neuroendocrine Tumor, Pancreatectomy, and Liver Embolization.

Expertise in
27
conditions
Dr. Joseph Uberti
Oncology
Expertise in
27
conditions
Dr. Joseph Uberti
Oncology

Office

4100 John R St, 
Detroit, MI 
 (487.6 miles away)
800-527-6266
Languages Spoken:
English
See accepted insurances

Joseph Uberti is an Oncologist in Detroit, Michigan. Dr. Uberti is highly rated in 27 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Elisabeth Heath

How do I make an appointment with Dr. Elisabeth Heath?

You can book an appointment with Dr. Elisabeth Heath by calling their office at 313-576-8715. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elisabeth Heath a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elisabeth Heath is classified as an Elite expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elisabeth Heath specialize in?

While Dr. Elisabeth Heath is a Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Renal Cell Carcinoma (RCC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Elisabeth Heath participate in research or clinical trials?

Yes. Dr. Elisabeth Heath has published 211 articles and abstracts on conditions like Prostate Cancer. You can view a list of Dr. Elisabeth Heath's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elisabeth Heath accept my insurance?

Dr. Elisabeth Heath accepts most major insurance plans, including Anthem BCBS and Blue Cross Blue Shield. We recommend calling the office directly at 313-576-8715 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Heath's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile